Article Sidebar
Published:
Oct 4, 2017Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of <i>CYP2C9</i>*3 gene polymorphism on lipid-lowering efficacy of fluvastatin in a Chinese hyperlipidemic population
Abstract
Purpose: To investigate the frequency of gene CYP2C9*3 in Chinese populations, and to analyze the impact of CYP2C9*3 genetic polymorphism on the cholesterol-lowering effect of fluvastatin in a Chinese hyperlipidemic population.
Methods: CYP2C9 genotype was determined by polymerase chain reaction - restriction fragment length polymorphism (PCR - RFLP) in 270 unrelated hyperlipidemic patients who were treated with 80mg fluvastatin monotherapy daily for 4 weeks and 250 healthy controls. Clinical data were collected prior to treatment with fluvastatin and 4 weeks after.
Results: In 270 hyperlipidemic patients, the frequency of CYP2C9*3 was 3.70 % which is significantly higher than in 250 healthy controls (2.60 %) (p < 0.01). After oral intake of fluvastatin 80 mg daily for 4 weeks, CYP2C9*1/*3 genotype was associated with a decrease in LDL-C levels (by 33.9 % in CYP2C9*1/*3 versus 24.5 % for CYP2C9*1/*1, p < 0.05) and with reduction of TC (by 36.4 % in CYP2C9*1/*3 versus 19.4 % in CYP2C9*1/*1, p < 0.05).
Conclusion: The frequency of CYP2C9*3 is 3.17 % in Chinese populations, and those who carry CYP2C9*3 mutation have a high risk of hyperlipidemia. CYP2C9*3 seems to increase the lipid-lowering effects of fluvastatin.
Keywords: Hyperlipidemia, Gene, CYP2C9, Polymorphism, Polymerase chain reaction, Restriction fragment length polymorphism, Fluvastatin
